Diagnostic Company to Partner with Scripps on Drug Discovery

(Wikimedia Commons)

Molecular Response, a diagnostic services company in San Diego, California says it has an agreement with Scripps Genomic Medicine, part of the Scripps Translational Science Institute also in San Diego, for joint discovery of oncology and cardiovascular drugs. Molecular Response develops molecular diagnostics as a companion to targeted and personalized therapeutics.

Under the terms of the agreement, Molecular Response will fund up to two discovery programs focusing on cancer research and heart disease. The company will also will share exclusive intellectual property rights with Scripps Genomic Medicine.

Scripps Translational Science Institute (STSI) conducts research to help move scientific knowledge from the lab to the patient bedside, bridging the gap between basic science and clinical trials. Scripps Genomic Medicine is a program in STSI that involves genotyping thousands of individuals to identify and define genes responsible for major diseases and human health overall.

Molecular Response discovers molecular markers that help predict patient response in clinical trials. The company says its results reduce risk and cost of drug development.

Read more: Diagnostics Companies Get European Grant for Bladder Cancer

*     *     *